These new generic implants are equivalent to the ones we know to be the safest and most reliable. Quite simply, the NHS is being offered the best performing product, at a lower cost. Having seen the evolution of orthopaedics in nearly 50 years’ experience with NHS patients, I believe the time has come for generic implants.

The Carter Review demonstrated that the NHS needs to improve consistency across Trusts, and access to generic implants for orthopaedics is a step in the right direction. Not only will this reduce variation in quality, significant costs could be saved without compromising patient safety. By improving procurement processes across the NHS we could be looking at saving £1 billion that can be reinvested in patient care.”

At the University Hospital of North Tees on November 29th, 2014. The hip implant that she received was an optimised equivalent, the world’s first generic hipimplant. A normal life again: her optimised equivalent hip has made it possible!

Given that extensive Technical Equivalence assessment was performed on the implant specifications, it is reasonable to assume the Orthimo implants will lead to the same clinical outcome as the branded reference implants; provided the same surgical competence is applied